Technology Platforms
Three Proprietary Nanotechnology Platforms
Each platform represents years of pharmaceutical R&D, validated through rigorous testing and ready for commercial licensing partnerships.
Scalable Graphene Production
Our proprietary manufacturing process produces pharmaceutical-grade monolayer graphene at a fraction of conventional costs, unlocking applications previously limited by material expense.
Manufacturing Advantages
- Proprietary monolayer graphene production methodology
- Significant cost reduction versus market rates of $500-5,000/gram
- Scalable manufacturing for pharmaceutical-volume production
- Consistent quality meeting pharmaceutical-grade specifications
- Applications spanning drug delivery, biosensors, and advanced materials
Pharmaceutical Applications
Graphene's unique properties enable next-generation drug delivery systems, including enhanced loading capacity for therapeutic compounds, improved biocompatibility profiles, and novel approaches to targeted delivery that were previously cost-prohibitive.
Cost Comparison
Cost advantage enables pharmaceutical-scale graphene applications for the first time.
Cost Advantage
Significant Reduction
Market Price
$500-5,000/gram
Quality
Monolayer Grade
Consistency
Pharmaceutical-Grade
Transdermal Nanoparticle Delivery Systems
Our nanoparticle delivery systems optimize particle size and surface characteristics to enhance penetration through the skin barrier, enabling targeted topical drug delivery with superior absorption profiles.
Mechanism of Action
Optimized nanoparticles penetrate the stratum corneum through intercellular pathways, delivering active pharmaceutical ingredients to target tissue layers with significantly enhanced bioavailability compared to conventional topical formulations.
Key Advantages
- Enhanced penetration through skin barrier for improved bioavailability
- Optimized particle size distribution for targeted tissue delivery
- Clinical validation for topical pharmaceutical applications
- Compatible with a wide range of active pharmaceutical ingredients
- Scalable manufacturing for pharmaceutical-grade production
Transdermal Delivery Process
Nanoparticle Formulation
Active ingredients encapsulated in optimized nanoparticles
Skin Barrier Penetration
Particles navigate intercellular pathways through the stratum corneum
Targeted Release
Controlled release at target tissue depth for sustained therapeutic effect
Enhanced Absorption
Superior bioavailability versus conventional topical formulations
Delivery Method
Topical Nanoparticle
Absorption
Enhanced Penetration
Validation
Pre-Clinical Data
Applications
Multi-Therapeutic
Blood-Brain Barrier Nanoemulsion Technology
Our proprietary nanoemulsion platform creates oil-in-water nano-suspensions with particles below 10nm, enabling drug delivery across the blood-brain barrier—opening CNS therapeutic pathways previously considered impossible.
Breakthrough Capability
The blood-brain barrier represents one of the greatest challenges in pharmaceutical development, blocking over 98% of therapeutic compounds from reaching the central nervous system. Our nanoemulsion technology achieves particle sizes below 10nm, enabling passage through the BBB and opening new treatment possibilities for neurological conditions.
Validation & Stability
- Particle sizes consistently below 10nm in nano-suspension formulations
- 4+ years of demonstrated stability with CBD formulations
- 18+ months validated stability for nanoemulsion compositions
- Oil-in-water formulation for superior biocompatibility
- Enables CNS drug delivery for neurological therapeutic applications
Particle Size Achievement
Our nanoemulsion particles are 10-20x smaller than typical nanoparticles, enabling BBB penetration.
Stability Data
Particle Size
<10nm
Formulation
Oil-in-Water
Stability
4+ Years (CBD)
Target
CNS Delivery
License Our Technology Platforms
Partner with AGCP to integrate our validated nanotechnology platforms into your pharmaceutical development pipeline.